160 related articles for article (PubMed ID: 38363912)
1. Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review.
Hui S; Zhao J; Huo T; Dong L; Xie Y; Wang X; Zhang M
Medicine (Baltimore); 2024 Feb; 103(7):e36953. PubMed ID: 38363912
[TBL] [Abstract][Full Text] [Related]
2. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review.
Burattini M; Falsetti L; Potente E; Rinaldi C; Bartolini M; Buratti L; Silvestrini M; Viticchi G
Rev Neurosci; 2022 Apr; 33(3):303-311. PubMed ID: 34508650
[TBL] [Abstract][Full Text] [Related]
3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
[TBL] [Abstract][Full Text] [Related]
6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
7. A Case of Recurrent Ischemic Stroke Involving Subacute, Progressive Intracranial Cerebral Arterial Sclerosis Prior to Diagnosis with JAK2-mutated Polycythemia Vera.
Nezu T; Aoki S; Ochi K; Sugihara S; Takahashi T; Hosomi N; Maruyama H; Matsumoto M
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):e4-6. PubMed ID: 26432562
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.
Fleischman RA
Am J Med Sci; 2013 Oct; 346(4):328-30. PubMed ID: 23588264
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
13. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
14. Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.
Toogeh G; Ferdowsi S; Naadali F; Alimoghaddam K; Ghavamzadeh A; Shirkoohi R; Ghaffari SH
Med Oncol; 2011 Dec; 28(4):1555-8. PubMed ID: 20499211
[TBL] [Abstract][Full Text] [Related]
15. JAK2 mutation-positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: a case report.
Kondo H; Watanabe R; Okazaki S; Kuriyama K; Ochi T; Yamada G; Sugiura A; Chiba H; Tsukada A; Taniuchi S; Igarashi T; Kudo M; Harigae H; Fujii H
Mod Rheumatol Case Rep; 2020 Jul; 4(2):289-295. PubMed ID: 33087019
[TBL] [Abstract][Full Text] [Related]
16. Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.
Benmalek R; Mechal H; Zahidi H; Mounaouir K; Arous S; Benouna MEG; Drighil A; Habbal R
J Med Case Rep; 2021 Feb; 15(1):76. PubMed ID: 33593422
[TBL] [Abstract][Full Text] [Related]
17. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
Means RT
Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
[TBL] [Abstract][Full Text] [Related]
19. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.
Sultan S; Irfan SM; Khan SR
Asian Pac J Cancer Prev; 2016; 17(3):1053-5. PubMed ID: 27039724
[TBL] [Abstract][Full Text] [Related]
20. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
